A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenoptin in Subjects with Phenylketonuria Who Have Elevated Phenylalanine Levels
Phase of Trial: Phase III
Latest Information Update: 29 Aug 2019
Price : $35 *
At a glance
- Drugs Sapropterin (Primary)
- Indications Phenylketonuria
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 29 Aug 2019 Status changed from recruiting to completed.
- 21 Jun 2019 This trial has been completed in Ireland.
- 18 Jul 2014 New trial record